Skip to main content
Back
TWST logo

Twist Bioscience Corporation

Data quality: 100%
TWST
NASDAQ Healthcare Medical - Diagnostics & Research
$44.50
▲ $2.43 (5.78%)
Mkt Cap: 2.73B
Day Range
$43.35 $45.57
52-Week Range
$23.30 $57.88
Volume
1,478,579
50D / 200D Avg
$45.44 / $34.84
Prev Close
$42.07

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E -35.1 0.4
P/B 5.8 2.9
ROE % -16.4 3.8
Net Margin % -20.6 3.9
Rev Growth 5Y % 29.9 10.0
D/E 0.3 0.2

Analyst Price Target

Hold
$48.25 +8.4%
Low: $41.00 High: $52.00
Forward EPS
-$1.81
Est. Revenue
440 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $1.25
$1.23 – $1.26
 760 M 2
FY2029 $0.50
$0.49 – $0.50
 660 M 3
FY2028 -$0.60
-$1.32 – $0.14
 580 M 6

Key Takeaways

Revenue grew 29.88% annually over 5 years — strong growth
Debt/Equity of 0.29 — conservative balance sheet
Negative free cash flow of -75.63M
PEG of 0.34 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 9.56%
Capital efficient — spends only 7.44% of revenue on capex

Growth

Revenue Growth (5Y)
29.88%
Revenue (1Y)20.32%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-16.43%
ROIC-16.75%
Net Margin-20.63%
Op. Margin-36.18%

Safety

Debt / Equity
0.29
Current Ratio3.64
Interest Coverage0.00

Valuation

P/E Ratio
-35.13
P/B Ratio5.77
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 20.32% Revenue Growth (3Y) 23.95%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 29.88% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 376.57M Net Income (TTM) -77.67M
ROE -16.43% ROA -12.10%
Gross Margin 50.72% Operating Margin -36.18%
Net Margin -20.63% Free Cash Flow (TTM) -75.63M
ROIC -16.75% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.29 Current Ratio 3.64
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -35.13 P/B Ratio 5.77
P/S Ratio 7.25 PEG Ratio 0.34
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 2.73B Enterprise Value 2.68B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 376.57M 312.97M 245.11M 203.57M 132.33M
Net Income -77.67M -208.73M -204.62M -217.86M -152.10M
EPS (Diluted) -1.30 -3.60 -3.60 -4.04 -3.15
Gross Profit 191.00M 133.35M 89.73M 84.24M 51.71M
Operating Income -136.26M -220.83M -217.16M -234.78M -152.73M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 641.86M 614.32M 776.40M 961.38M 702.10M
Total Liabilities 168.90M 141.63M 152.97M 171.99M 121.28M
Shareholders' Equity 472.96M 472.69M 623.43M 789.39M 580.82M
Total Debt 137.32M 85.03M 94.07M 94.91M 62.92M
Cash & Equivalents 183.05M 226.32M 286.47M 378.69M 465.83M
Current Assets 332.97M 346.78M 424.26M 596.48M 546.50M
Current Liabilities 91.41M 71.01M 73.32M 90.66M 63.05M

Strategy Scores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#92 of 146
36

Recent Activity

Entered Full Throttle
Mar 24, 2026